Royal Bank of Canada
NVO

Royal Bank of Canada’s Novo Nordisk NVO Stock Holding History

Royal Bank of Canada’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,700
Closed -$1.21M – 7410
2023
Q4 		$1.21M Buy
+11,700
New +$1.16M ﹤0.01% 3513

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Royal Bank of Canada's NVO Position: Q1 2026 in Review

Royal Bank of Canada increased its Novo Nordisk (NVO) stake by 3.2% in Q1 2026, buying an estimated $6.7M and bringing the position to 4,527,779 shares worth $166M. The position accounts for 0.03% of the portfolio, ranked #457.

Royal Bank of Canada first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $842M in Q2 2024. 1,276 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Royal Bank of Canada held 4,527,779 shares of Novo Nordisk worth $166M as of Q1 2026.
  • Royal Bank of Canada bought 141,376 Novo Nordisk shares in Q1 2026, an estimated $6.7M.
  • Novo Nordisk made up 0.03% of Royal Bank of Canada's portfolio in Q1 2026, its #457 holding.
  • Royal Bank of Canada first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Novo Nordisk position peaked at $842M in Q2 2024.
  • 1,276 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.